Opinion

A new, market-driven model of drug development and commercialization is appearing*

Looking at 'cost' and 'value' under different evaluation processes

Looking at the essential value of well-managed supply chains

HDMA seeks to encourage more outreach to business partners and government

Despite a flurry of specialty pharmaceuticals in innovative formats, traditional powder-based dosages will always be a mainstay

A Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets

Fees paid to FDA by small generic manufacturers are financially 'unfair'

The pharma industry needs to go farther in adapting to new marketplace realities

The second edition of an essential business planner's library

"If we had asked them, they would have asked for faster horses." ~ Henry Ford

While the pharma industry is growing more dependent on companion diagnostics, test developers face an uncertain business model

Logistics managers in life sciences and personal care focus on transportation capacity

Medical marijuana and biosimilars are two topics where 'the will of the people' push decisions

A family-owned pharmaceutical manufacturer plots a 21st-century growth plan

Will formularies become a consumer's concern for healthcare provision?

Internal compliance reviews are not enough; life sciences companies need to assess their third-party business partners

Defining 'market access'

Some state-level changes give an indication of what to prepare for

An 'expectations convergence' is building in how drug efficacy aligns with patient outcomes

The Drug Supply Chain Security Act creates uncertainty about which trading partners have responsibility for product verification

Modern training technologies make the prospect of days-long training courses an obsolete practice

Doing business in China is undergoing important changes